TY - JOUR
T1 - Classification of childhood white matter disorders using proton MR spectroscopic imaging
AU - Bizzi, Alberto
AU - Castelli, G.
AU - Bugiani, M.
AU - Barker, P. B.
AU - Herskovits, E. H.
AU - Danesi, U.
AU - Erbetta, A.
AU - Moroni, I.
AU - Farina, L.
AU - Uziel, G.
PY - 2008/8
Y1 - 2008/8
N2 - BACKGROUND AND PURPOSE: Childhood white matter disorders often show similar MR imaging signal-intensity changes, despite different underlying pathophysiologies. The purpose of this study was to determine if proton MR spectroscopic imaging (1H-MRSI) may help identify tissue pathophysiology in patients with leukoencephalopathies. MATERIALS AND METHODS: Seventy patients (mean age, 6; range, 0.66-17 years) were prospectively examined by 1H-MRSI; a diagnosis of leukoencephalopathy due to known genetic defects leading to lack of formation, breakdown of myelin, or loss of white matter tissue attenuation (rarefaction) was made in 47 patients. The diagnosis remained undefined (UL) in 23 patients. Patients with definite diagnoses were assigned (on the basis of known pathophysiology) to 3 groups corresponding to hypomyelination, white matter rarefaction, and demyelination. Choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) signals from 6 white matter regions and their intra- and intervoxel (relative to gray matter) ratios were measured. Analysis of variance was performed by diagnosis and by pathophysiology group. Stepwise linear discriminant analysis was performed to construct a model to predict pathophysiology on the basis of 1H-MRSI, and was applied to the UL group. RESULTS: Analysis of variance by diagnosis showed 3 main metabolic patterns. Analysis of variance by pathophysiology showed significant differences for Cho/NAA (P < .001), Cho/Cr (P < .004), and NAA/Cr (P < .002). Accuracy of the linear discriminant analysis model was 75%, with Cho/Cr and NAA/Cr being the best parameters for classification. On the basis of the linear discriminant analysis model, 61% of the subjects in the UL group were classified as hypomyelinating. CONCLUSION: 1H-MRSI provides information on tissue pathophysiology and may, therefore, be a valuable tool in the evaluation of patients with leukoencephalopathies.
AB - BACKGROUND AND PURPOSE: Childhood white matter disorders often show similar MR imaging signal-intensity changes, despite different underlying pathophysiologies. The purpose of this study was to determine if proton MR spectroscopic imaging (1H-MRSI) may help identify tissue pathophysiology in patients with leukoencephalopathies. MATERIALS AND METHODS: Seventy patients (mean age, 6; range, 0.66-17 years) were prospectively examined by 1H-MRSI; a diagnosis of leukoencephalopathy due to known genetic defects leading to lack of formation, breakdown of myelin, or loss of white matter tissue attenuation (rarefaction) was made in 47 patients. The diagnosis remained undefined (UL) in 23 patients. Patients with definite diagnoses were assigned (on the basis of known pathophysiology) to 3 groups corresponding to hypomyelination, white matter rarefaction, and demyelination. Choline (Cho), creatine (Cr), and N-acetylaspartate (NAA) signals from 6 white matter regions and their intra- and intervoxel (relative to gray matter) ratios were measured. Analysis of variance was performed by diagnosis and by pathophysiology group. Stepwise linear discriminant analysis was performed to construct a model to predict pathophysiology on the basis of 1H-MRSI, and was applied to the UL group. RESULTS: Analysis of variance by diagnosis showed 3 main metabolic patterns. Analysis of variance by pathophysiology showed significant differences for Cho/NAA (P < .001), Cho/Cr (P < .004), and NAA/Cr (P < .002). Accuracy of the linear discriminant analysis model was 75%, with Cho/Cr and NAA/Cr being the best parameters for classification. On the basis of the linear discriminant analysis model, 61% of the subjects in the UL group were classified as hypomyelinating. CONCLUSION: 1H-MRSI provides information on tissue pathophysiology and may, therefore, be a valuable tool in the evaluation of patients with leukoencephalopathies.
UR - http://www.scopus.com/inward/record.url?scp=49749135519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49749135519&partnerID=8YFLogxK
U2 - 10.3174/ajnr.A1106
DO - 10.3174/ajnr.A1106
M3 - Article
C2 - 18483189
AN - SCOPUS:49749135519
SN - 0195-6108
VL - 29
SP - 1270
EP - 1275
JO - American Journal of Neuroradiology
JF - American Journal of Neuroradiology
IS - 7
ER -